Alzheimer’s Study in People at Risk, a Response to FDA Call for Early Research, Now Recruiting

Alzheimer’s Study in People at Risk, a Response to FDA Call for Early Research, Now Recruiting
The U.S. Food and Drug Administration (FDA) issued a draft guidance in 2013 to encourage research  in people at the earliest stages of Alzheimer’s disease, with no symptoms or no obvious symptoms. The update has had effect, with new clinical trials looking at Alzheimer's patients without noticeable dementia, when they might possibly benefit most from treatment, the agency reported in a news release. Previous studies have shown that there is a delay of several years between the first changes in a patient’s brain and the onset of Alzheimer’s symptoms, and some scientists suggest that the greatest benefits of treatment are most likely only very early in the disease course. The FDA intended that the draft prod research into early stage Alzheimer’s therapies, with the document serving as a platform for continued discussions among the agency, industry sponsors of drug therapies, the scientific community and the general public. Among the clinical trials underway in response — and now recruiting participants — is the ‘A4 Study’ (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s), a landmark public-private effort funded by the National Institute on Aging, Eli Lilly and Company, and several philanthropic organizations. People being recruited are ages 65 to 85 with unimpaired thinking and memory function, but thought to be at risk for developing Alzheimer’s as determined by an advanced brain scan. The three-ye
Subscribe or to access all post and page content.

One comment

  1. Sharon Biggins says:

    I have taken the prescreened test and am eligible. My family history is that my grandmother, mother, (both deceased) and 2 aunts have had and in my aunts cases are still living and in nursing homes with alzheimer’s. I am 74 years old, in excellent health, in the gym 5 times per week, and am very interested in this research.

Leave a Comment

Your email address will not be published. Required fields are marked *